Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease

JAMA

Volumn 279, Issue 4, 1998, Pages 287-291

  Roose, Steven P ^a   Laghrissi Thode, Fouzia ^b   Kennedy, John S ^c   Nelson, J Craig ^e   Bigger, J Thomas ^a   Pollock, Bruce G ^b   Gaffney, Andrew ^c,d   Narayan, Meena ^e   Finkel, Mitchell S ^f   McCafferty, James ^g   Gergel, Ivan ^g  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; VASODILATOR AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS TACHYCARDIA;

EID: 0032573877     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.4.287     Document Type: Article

References (32)

1. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270:1819-1825.
2. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
3. Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry. 1989;50(suppl):1-18.
4. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl Med. 1989;321:406-412.
5. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227-233.
6. Bigger JT Jr. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Am J Cardiol, 1990;65:3D-10D.
7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
8. Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischaemia and encainide/flecainide treatment: a proosed mechanism for the increased mortality in CAST I. Br Heart J. 1995;74:631-635.
9. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk/ benefit reconsidered. JAMA. 1993;269:2673-2675.
10. Cooper GL. The safety of fluoxetine: an update. Br J Psychiatry. 1988;153(suppl 3):77-86.
11. Kuhs H, Rudolf GAE. Cardiovascular effects of paroxetine. Psychopharmacology. 1990;102:379-382.
12. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry. 1985;46(3, pt 2):42-44.
13. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985;46(3, pt 2): 59-67.
14. Upward JW, Edwards JG, Goldie A, Waller DG. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol. 1988;26: 399-402.
15. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EGV, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. In press.
16. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. The Cardiac Arrhythmia Pilot Study. Am J Cordial. 1986;57:91-95.
17. Vohra J, Burrows GD, Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975;5:7-11.
18. Freyschuss U, Sjoqvist F, Tuck D, Asberg M. Circulatory effects in man of nortriptyline, a tricyclic antidepressant drug. Pharmacol Clin. 1970;2:68-71.
19. Ziegler VE, Co BT, Biggs JT. Plasma nortriptyline levels and ECG findings. Am J Psychiatry. 1977;134:441-443.
20. Giardina EGV, Barnard JT, Johnson LL, Saroff AL, Bigger JT Jr, Louie M. The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations. J Am Coll Cardial. 1986;7:1363-1369.
21. Roose SP, Glassman AH, Giardina EGV, Walsh BT, Woodring S, Bigger JT Jr. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 1987;44:273-275.
22. Kantor SJ, Glassman AH, Bigger JT Jr, Perel JM, Giardina EGV. The cardiac effects of therapeutic plasma concentrations of imipramine. Am J Psychiatry. 1978;135:534-538.
23. Giardina EGV, Bigger JT Jr, Glassman AH, et al. Desmethylimipramine and imipramine on left ventricular function and the ECG: a randomized crossover design. Int J Cardiol. 1983;2:375-385.
24. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113: 1489-1494.
25. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991; 121:172-177.
26. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736-749.
27. Kleiger RE, Miller JP, Bigger JT Jr, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256-262.
28. Roose SP, Dalack GW, Woodring S. Death, depression, and heart disease. J Clin Psychiatry. 1991; 52(suppl 6):34-39.
29. Yeragani VK, Pohl RB, Balon R, et al. Effect of imipramine treatment on heart rate variability measures. Biol Psychiatry. 1992;26:27-32.
30. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol. 1995;76:562-564.
31. Walsh BT, Giardina EGV, Sloan RP, Greenhill L, Goldfein J. Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry. 1994;33:191-197.
32. Schroeder JS, Mullin AV, Elliott GR, etal. Cardiovascular effects of desipramine in children. J Am Acad Child Adolesc Psychiatry. 1989;28:376-379.